Aviceda starts Phase 2 for macular degeneration therapy

 Aviceda Therapeutics, a private clinical-stage biotech company focused on developing next generation immuno-modulators by harnessing the power of glycobiology to alleviate chronic, non-resolving inflammation, announced the dosing of its first patient with AVD-104 in its Phase 2 SIGLEC Trial today by Ashkan Abbey, MD of Texas Retina Associates in Dallas. This lead intravitreal asset is a novel glycan-coated nanoparticle, supported by a uniquely strong pre-clinical in vivo efficacy and safety profile, used for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). “I am honored to be the first to dose a new agent that we hope will usher in a generation of safe treatments for GA with better outcomes than were ever possible before,” said Dr. Abbey.

https://www.biospace.com/article/releases/aviceda-announces-dosing-of-first-patient-with-avd-104-a-novel-glyco-mimetic-nanoparticle-for-the-treatment-of-geographic-atrophy-from-macular-degeneration-in-the-phase-2-siglec-trial/